Asset Details
Do you wish to reserve the book?
Potent monoclonal antibody–mediated neutralization of a divergent Hendra virus variant
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Potent monoclonal antibody–mediated neutralization of a divergent Hendra virus variant
Do you wish to request the book?
Potent monoclonal antibody–mediated neutralization of a divergent Hendra virus variant
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Potent monoclonal antibody–mediated neutralization of a divergent Hendra virus variant
2022
Overview
Hendra virus (HeV) and Nipah virus (NiV) are deadly zoonotic Henipaviruses (HNVs) responsible for recurrent outbreaks in humans and domestic species of highly fatal (50 to 95%) disease. A HeV variant (HeV-g2) of unprecedented genetic divergence has been identified in two fatally diseased horses, and in two flying fox species in regions of Australia not previously considered at risk for HeV spillover. Given the HeV-g2 divergence from HeV while retaining equivalent pathogenicity and spillover potential, understanding receptor usage and antigenic properties is urgently required to guide One Health biosecurity. Here, we show that the HeV-g2 G glycoprotein shares a conserved receptor tropism with prototypic HeV and that a panel of monoclonal antibodies recognizing the G and F glycoproteins potently neutralizes HeV-g2– and HeV G/F–mediated entry into cells. We determined a crystal structure of the Fab fragment of the hAH1.3 antibody bound to the HeV G head domain, revealing an antigenic site associated with potent cross-neutralization of both HeV-g2 and HeV. Structure-guided formulation of a tetravalent monoclonal antibody (mAb) mixture, targeting four distinct G head antigenic sites, results in potent neutralization of HeV and HeV-g2 and delineates a path forward for implementing multivalent mAb combinations for postexposure treatment of HNV infections.
Publisher
National Academy of Sciences
Subject
Antibodies, Monoclonal - chemistry
/ Antibodies, Monoclonal - immunology
/ Antibodies, Neutralizing - chemistry
/ Antibodies, Neutralizing - immunology
/ Antibodies, Viral - chemistry
/ Antibodies, Viral - immunology
/ Antigens
/ Horses
/ Humans
/ Immunoglobulin Fab Fragments - chemistry
/ Tropism
/ Viral Envelope Proteins - genetics
/ Viral Envelope Proteins - immunology
/ Viruses
